Targeting the incretin/glucagon system with triagonists An even more advanced step towards the generation of an effective anti-obesity pharmacotherapy is the report of a single peptide capable of simultaneously activating the receptors for glucagon, GLP-1, and GIP by using a highly effective, balanced triagonist structure [25]
However, a few studies did find DPP-4is to be associated with a reduced risk of fractures compared to non-DPP-4i use (26, 27) or compared to glitazones (20)
The main advantage here is that it allows for finer control over smaller doses, as each unit on the syringe contains less active peptide
This means B12 deficiency is real and underdiagnosed, but it is not universal and not everyone experiencing fatigue has a B12 problem
Histamine H2 receptor antagonists, such as cimetidine ( Tagamet ), famotidine ( Pepcid ), and ranitidine ( Zantac ), that are used to treat peptic ulcer disease
Full-dose GLP-1 therapy can sometimes be associated with low energy during early use